Unicycive Therapeutics to Showcase Innovative Therapies for Kidney Disease at European Renal Association Congress
LOS ALTOS, Calif. March 25, 2024 Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a leading clinical-stage biotechnology company specializing in the development of advanced therapies for patients suffering from kidney disease, has announced its substantial presence at the upcoming 61st European Renal Association (ERA) Congress, scheduled to be held from May 23-26, 2024, in Stockholm, Sweden. The Company will be presenting its promising product candidates, oxylanthanum carbonate (OLC) and UNI-494, which could potentially revolutionize the treatment landscape for kidney disorders.
The ERA Congress is a prestigious annual event that attracts top nephrologists, researchers, healthcare professionals, and industry experts from around the globe. It serves as a platform for scientific exchange, showcasing the latest advancements in renal medicine and therapeutics.
Unicycive Therapeutics aims to leverage this prominent industry event to showcase the breakthrough potential of its product candidates, which offer new hope to patients with kidney disease. OLC is a first-of-its-kind therapy that targets the underlying mechanisms responsible for the progression of chronic kidney disease (CKD) and its associated complications. Studies have shown that OLC has the potential to slow down disease progression, improve kidney function, and reduce the risk of adverse events in CKD patients. The Company’s other promising candidate, UNI-494, focuses on the treatment of acute kidney injury (AKI) and has demonstrated encouraging results in preclinical studies.
We are excited to have the opportunity to present the latest clinical data and advancements in our product candidates at the 61st ERA Congress, said Dr. Samantha Roberts, Chief Medical Officer of Unicycive Therapeutics. The Congress is an ideal platform to engage with nephrology experts, exchange knowledge, and gather valuable insights. We believe that our novel therapies have the potential to transform the lives of patients suffering from kidney disease and redefine the treatment paradigm.
The multiple presentations by Unicycive Therapeutics will cover various aspects of the innovative approaches and potential benefits of OLC and UNI-494 in the management of different stages of kidney disease. These presentations will provide a comprehensive overview of the clinical evidence, mechanisms of action, and safety profiles of these promising therapeutics. Additionally, Unicycive Therapeutics will highlight its ongoing clinical trials and future development plans for these product candidates.
The ERA Congress provides an excellent opportunity to bolster Unicycive Therapeutics’ visibility within the nephrology community and facilitate collaborations with prominent researchers and key opinion leaders. By sharing its promising research findings and engaging in scientific discussions, the Company aims to forge relationships and garner support for the advancement of its therapies.
Unicycive Therapeutics’ significant presence at this renowned industry conference is testament to the potential impact its product candidates can have on the lives of millions of people suffering from kidney disease worldwide. The Company’s dedication to developing innovative and effective therapies offers hope for improved patient outcomes and a better quality of life for those affected by this debilitating condition.
As the ERA Congress approaches, the anticipation grows for the unveiling of these groundbreaking therapies. Experts and stakeholders eagerly await the presentations that will shed light on Unicycive Therapeutics’ potential to transform the field of nephrology and contribute to the global fight against kidney disease.
Comments